ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring

Martin H Voss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.